ADAG Stock Overview
A clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Adagene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.19 |
| 52 Week High | US$4.38 |
| 52 Week Low | US$1.35 |
| Beta | 0.58 |
| 11 Month Change | -23.04% |
| 3 Month Change | -25.64% |
| 1 Year Change | 52.33% |
| 33 Year Change | -74.76% |
| 5 Year Change | n/a |
| Change since IPO | -92.69% |
Recent News & Updates
Recent updates
Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Oct 10
The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically
Oct 05Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M
Aug 30Micro-cap Adagene surges after hours on $10M share buyback
Jun 29Shareholder Returns
| ADAG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.6% | 2.4% | 2.2% |
| 1Y | 52.3% | 16.2% | 31.7% |
Return vs Industry: ADAG exceeded the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: ADAG exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| ADAG volatility | |
|---|---|
| ADAG Average Weekly Movement | 14.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ADAG's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ADAG's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 174 | Peizhi Luo | www.adagene.com |
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company’s product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs.
Adagene Inc. Fundamentals Summary
| ADAG fundamental statistics | |
|---|---|
| Market cap | US$100.05m |
| Earnings (TTM) | -US$31.85m |
| Revenue (TTM) | US$815.75k |
119.0x
P/S Ratio-3.0x
P/E RatioIs ADAG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADAG income statement (TTM) | |
|---|---|
| Revenue | US$815.75k |
| Cost of Revenue | US$0 |
| Gross Profit | US$815.75k |
| Other Expenses | US$32.67m |
| Earnings | -US$31.85m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,904.31% |
| Debt/Equity Ratio | 36.3% |
How did ADAG perform over the long term?
See historical performance and comparison